• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials.

作者信息

Sánchez-Rico Marina, Rezaei Katayoun, Lenze Eric J, Limosin Frédéric, Hoertel Nicolas

出版信息

Ann Pharmacother. 2024 Nov;58(11):1153-1155. doi: 10.1177/10600280231211304. Epub 2023 Nov 28.

DOI:10.1177/10600280231211304
PMID:38014845
Abstract
摘要

相似文献

1
Efficacy of Fluvoxamine in Outpatients With COVID-19: Understanding Conflicting Conclusions From 2 Recent Meta-Analyses of the Same Clinical Trials.氟伏沙明对新冠门诊患者的疗效：解读对相同临床试验的两项近期荟萃分析相互矛盾的结论
Ann Pharmacother. 2024 Nov;58(11):1153-1155. doi: 10.1177/10600280231211304. Epub 2023 Nov 28.
2
Fluvoxamine for COVID-19?氟伏沙明用于治疗新冠病毒肺炎？
Med Lett Drugs Ther. 2021 May 3;63(1623):69-70.
3
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence.氟伏沙明治疗 SARS-CoV-2 感染的早期治疗：当前证据综述。
Drugs. 2021 Dec;81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. Epub 2021 Dec 1.
4
Fluvoxamine and long COVID: Post-acute recovery.氟伏沙明与长期新冠：急性后期恢复
Rev Med Virol. 2024 Jul;34(4):e2557. doi: 10.1002/rmv.2557.
5
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.选择性 5-羟色胺再摄取抑制剂在 COVID-19 管理中的疗效和安全性：系统评价和荟萃分析。
Clin Microbiol Infect. 2023 May;29(5):578-586. doi: 10.1016/j.cmi.2023.01.010. Epub 2023 Jan 16.
6
Fluvoxamine for the treatment of COVID-19.氟伏沙明治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391. doi: 10.1002/14651858.CD015391.
7
A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.一项系统评价和荟萃分析，研究了氟伏沙明治疗 COVID-19 病情恶化、死亡和长期 COVID 并发症的剂量和时间疗效。
Sci Rep. 2024 Jun 12;14(1):13462. doi: 10.1038/s41598-024-64260-9.
8
Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?选择性5-羟色胺再摄取抑制剂抗抑郁药氟西汀和氟伏沙明能否降低COVID-19患者的死亡率？
JAMA Netw Open. 2021 Nov 1;4(11):e2136510. doi: 10.1001/jamanetworkopen.2021.36510.
9
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.氟伏沙明早期治疗对 COVID-19 患者急诊和住院风险的影响：TOGETHER 随机、平台临床试验。
Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28.
10
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.抗抑郁药对住院患者 COVID-19 严重程度的影响：系统评价和荟萃分析。
PLoS One. 2022 Oct 6;17(10):e0267423. doi: 10.1371/journal.pone.0267423. eCollection 2022.

引用本文的文献

1
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.使用氟伏沙明、溴己新、赛庚啶和氯硝柳胺进行早期治疗以预防有症状的COVID-19患者临床病情恶化：一项随机临床试验。
EClinicalMedicine. 2024 Mar 14;70:102517. doi: 10.1016/j.eclinm.2024.102517. eCollection 2024 Apr.
2
Excess mortality and its causes among older adults with schizophrenia versus those with bipolar disorder and major depressive disorder: a 5-year prospective multicenter study.精神分裂症老年患者与双相情感障碍和重度抑郁症老年患者的超额死亡率及其原因：一项为期5年的前瞻性多中心研究。
Eur Arch Psychiatry Clin Neurosci. 2025 Apr;275(3):595-605. doi: 10.1007/s00406-023-01752-1. Epub 2024 Jan 31.